Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)
This amendment summary clarifies several requirements for the THRIVE program proposal. Key changes include making cost share strongly encouraged instead of mandatory and removing the requirement for multi-party teaming. The proposal process now includes a required virtual PowerPoint presentation, with slides due by December 22, 2025, and presentations scheduled from January 5 to January 16, 2026. Several proposal volumes and sections, including the Cost Proposal and Administrative Requirements, have been revised, with some only required if a proposer is invited to negotiate. The Q&A deadline has been extended to October 30, 2025.
Links (1)
Attachments (13)
Data sourced from SAM.gov.
View Official Posting »